Skip to main content
wftp-temp

Our mission is clear — we discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our sense of urgency is real — we work every day to push the boundaries of scientific discovery and to make a meaningful difference in the lives of patients. We are committed to developing a 21st century workforce that is powerfully diverse and broadly inclusive, capable of discovering and developing important new medicines for patients around the world. It’s what we do. It’s why we do it.

“At Bristol-Myers Squibb, we are looking forward to an exciting future. We will build on the strong foundationof 2018 to grow our business and to help more patients. We have great medicines. We have great people.”

– Giovanni Caforio, M.D.,
Chairman of the Board and Chief Executive Officer

We come to work every day with one mission in mind: to discover, develop, and deliver transformational medicines to help patients facing serious diseases. This is what we do. This is who we are.

In 2018, performance was strong across the company and created great momentum for our business. We expanded the indications of our oncology portfolio with the important approval of Opdivo plus low-dose Yervoy for the treatment of renal cell carcinoma (RCC) in the U.S. and Europe. We reached an important milestone with Eliquis in the U.S., taking a leadership position in the prevention of stroke for patients with atrial fibrillation. We advanced a broad and deep pipeline in oncology, cardiovascular disease, fibrosis, and immunoscience. And we continued our efforts to be a good global citizen through our green initiatives, by investing in our local communities, and by supporting those in need.

Global Sales Map
Global Sales Global Sales Continue reading the ceo letter

Global Diversity & Inclusion

People & Business Resource Groups

Our People and Business Resource Groups (PBRG) leverage the diverse experiences and perspectives of our employees and drive transformative business results.

RBGS
PBRG logos-C

Patient Stories

Carol Willis
Ken Simpson
Jessie Stern
Samantha Wesson
Development Portfolio By Therapeutic Area
Secure the future

A Legacy of Hope

As a global pharmaceutical company with a strong portfolio of HIV therapies, Bristol-Myers Squibb took on a major role in the fight against the disease. In 1999, together with the Bristol-Myers Squibb Foundation, the company launched SECURE THE FUTURE, a groundbreaking commitment that helped transform how healthcare was delivered in the region.

Secure the future - 20th anniversary

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.